How Technology Has Helped Shape The Innovation Of Drug Dosage Forms And Support Patient-Centric Goals

Source: Pfizer CentreOne Oral Solids

Technological innovations are enabling high potency active pharmaceutical ingredients (HPAPIs) — traditionally found in most parenteral formulations — to be used in more OSD treatments, allowing the pharmaceutical industry to move away from a one-size-fits-all approach to drug development and towards treatments that are more tailored to patient populations. Delivering highly potent drug formulations via parenteral forms often requires administration in a clinical setting by healthcare professionals to ensure safety and compliance. However, delivering these drugs in OSD form via tablets or capsules is preferable for both patients and healthcare professionals, as they boost patient compliance and convenience while freeing up time for healthcare professionals.

However, delivering HPAPIs in OSD form requires developers to overcome significant challenges to solve the API release issues of highly potent formulations. When partnering with a CDMO to formulate and manufacture your HPAPI drug product, it is important to look for not only comprehensive technical capabilities but also experience and success at commercializing complex OSD formulations. Learn how delivering these drugs in OSD form via tablets or capsules can help boost patient compliance and consider the complex formulation challenges inherent to HPAPI development and manufacturing.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Delivery Leader